Acta Scientific Ophthalmology (ISSN: 2582-3191)

Research Article Volume 5 Issue 3

Comparative Effectiveness of Hyperbaric Oxygen Therapy Versus Bevacizumab Therapy in Patients with Vascular Obstructions of the Retina

Lic Rodrigo Ojeda Salamanca1, Lic Cristopher Campos Cifuentes1 and Mg Hugo Berríos Arvey2*

1School of Medical Technology, San Sebastián University, Chile
2School of Medical Technology, Mayor University, Chile

*Corresponding Author: Mg Hugo Berríos Arvey, School of Medical Technology, Mayor University, Chile.

Received: December 28, 2021; Published: February 23, 2022


Aim: To compare the evidence of primary studies on the effectiveness of hyperbaric oxygen therapy and Bevacizumab in patients with retinal vascular obstructions.

Materials and methods: A systematic review was carried out without meta-analysis of 123 primary studies, 98 of which were excluded due to exclusion criteria, the remaining 25 studies were submitted to internal and external validity criteria, leaving 20 for research use.

Results: No significant differences were observed between the efficacy of hyperbaric oxygen therapy and Bevacizumab (0.73 and 0.78), respectively. In contrast, the cost of both benefits had a significant variation between both therapies ($20.70 and $475.42 dollars approximately).

Conclusions: Although both therapies have demonstrated efficacy in retinal vascular obstructions, the cost per individual benefit makes hyperbaric oxygen therapy more convenient and at the same time less invasive than other ophthalmologic treatments indicated for these pathologies.

Keywords: Hyperbaric Oxygen Therapy; Bevacizumab; Retinal Vascular Obstruction; Hyperbaric Chamber; RVCO; CRAO


  1. Mario Bradvica., et al. "Retinal Vascular Occlusions". IntechOpen - Open Science Open Minds | IntechOpen, March 7, (2012).
  2. Banks Anderson William. "Retinal Oxygen Utilization Measured by Hyperbaric Blackout". JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association, December 1, (1964).
  3. Thom Stephen R. "Hyperbaric Oxygen – Its Mechanisms and Efficacy". Plastic and Reconstructive Surgery 127 (2011): 131S-141S.
  4. Hajhosseini Babak. "Hyperbaric Oxygen Therapy: Descriptive Review of the Technology and Current Application in Chronic Wounds". Plastic and Reconstructive Surgery9 (2020): e3136.
  5. Stahl, Andreas. "Bevacizumab in Retinal Vein Occlusion-Results of a Prospective Case Series - PubMed". Graefe's Archive for Clinical and Experimental Ophthalmology 10(2007):1429-1436.
  6. Gagnier Joel J. "The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development - PubMed". BMJ Case Report October 23, (2013).


Citation: Mg Hugo Berríos Arvey., et al. “Comparative Effectiveness of Hyperbaric Oxygen Therapy Versus Bevacizumab Therapy in Patients with Vascular Obstructions of the Retina".Acta Scientific Ophthalmology 5.3 (2022): 43-47.


Copyright: © 2022 Mg Hugo Berríos Arvey., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US